Market Research Logo

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2016

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2016’, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD)
  • The report reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics and enlists all their major and minor projects
  • The report assesses Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD)
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Non Alcoholic Fatty Liver Disease (NAFLD) Overview
Therapeutics Development
Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) - Overview
Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics under Development by Companies
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics under Investigation by Universities/Institutes
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Non Alcoholic Fatty Liver Disease (NAFLD) - Products under Development by Companies
Non Alcoholic Fatty Liver Disease (NAFLD) - Products under Investigation by Universities/Institutes
Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development
Arisaph Pharmaceuticals, Inc.
AstraZeneca Plc
Betagenon AB
Can-Fite BioPharma Ltd.
Cerenis Therapeutics Holding SA
Conatus Pharmaceuticals Inc.
Corcept Therapeutics Incorporated
Daewoong Pharmaceutical Co., Ltd.
Dimerix Bioscience Pty Ltd
Dr. Falk Pharma GmbH
DURECT Corporation
Eternygen GmbH
Galmed Pharmaceuticals Ltd.
Huons Co., Ltd.
Kyorin Pharmaceutical Co., Ltd.
Matinas BioPharma Holdings, Inc.
Novartis AG
NovaTarg Therapeutics, Inc
Osel, Inc.
Sancilio & Company, Inc.
TaiwanJ Pharmaceuticals Co., Ltd.
TCM Biotech International Corp
Tobira Therapeutics, Inc.
Zafgen Inc.
Zydus Cadila Healthcare Limited
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(leucine + PDE5 Inhibitor) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AC-261066 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aramchol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARI-3037MO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-4076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBM-588 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cenicriviroc mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CER-209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CORT-118335 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dapagliflozin propanediol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DMX-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUR-928 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWP-10292 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emricasan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FLB-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HU-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDT-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAT-8800 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MN-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
norursodeoxycholic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
O-304 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oltipraz - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pradigastat sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RT-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RT-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
saroglitazar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-410 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TCM-606F - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZGN-839 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects
Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products
Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones
Featured News & Press Releases
Jun 10, 2016: NuSirt Biopharma Presents Data on NS-0200 at American Diabetes Association's 76th Annual Scientific Sessions
Jun 07, 2016: Galmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China
Jun 01, 2016: Galmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial
May 24, 2016: Two presentations highlighting Zydus drug, Lipaglyn will be featured at the AACE Annual meeting
Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease
Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study
Jan 11, 2016: Can-Fite Announces Update on CF102
Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-928
Dec 10, 2015: NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment
Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease
Oct 08, 2015: NuSirt Biopharma Plans Clinical Trial in Non-Alcoholic Fatty Liver Disease
May 18, 2015: DURECT Announces Positive Results from DUR-928 Multi-Dose Phase 1 Study
Apr 23, 2015: Conatus Clinical Results at EASL Meeting Support Emricasan Registration Pathway in NASH
Apr 08, 2015: Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting
Mar 30, 2015: DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2016
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by AstraZeneca Plc, H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Betagenon AB, H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Can-Fite BioPharma Ltd., H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Cerenis Therapeutics Holding SA, H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Conatus Pharmaceuticals Inc., H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Corcept Therapeutics Incorporated, H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dr. Falk Pharma GmbH, H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by DURECT Corporation, H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eternygen GmbH, H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed Pharmaceuticals Ltd., H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Huons Co., Ltd., H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Novartis AG, H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NovaTarg Therapeutics, Inc, H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Osel, Inc., H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Sancilio & Company, Inc., H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TCM Biotech International Corp, H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Tobira Therapeutics, Inc., H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zafgen Inc., H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects (Contd..1), H2 2016
Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2016
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report